Pfizer SWOT Analysis

Pfizer, a number one pharmaceutical company with its research head quarters in Groton and Connecticut was found in 1849. It mainly produces antibiotics, anti-inflammatory drugs, antifungal drugs, neuropathic pain relievers and lipitor as its main products.

Strengths

• High budget pharmaceutical industries having the revenue of $50 billion.

• Its number one pharmaceutical from sales point of view and its marketing infrastructure is well established throughout the world.

• Pfizer has 7.5% of ranking corporation market share.

• Pfizer has a global working network with 95,000 workers around the globe, in all the continents.

• The company profits has gradually been improved from $48.2 billion in  2008 to $50 billion in 2009 and then jumping directly to 67.8 billion, which means that its sale has  increased from 16.02 to 22.89 %, which is the big achievement in rising revenues.

• Their research and development sector is highly established and in good strength, and that is its primary business strategy.

• Their therapeutic coverage is very large and the innovative researchers are broadening it further.

• Their reputation has been established for years on number of products.

• It has wide range of area being worked, that includes Human health, animal health, customer health and corporate groups.

• Involved in licensing agreements with different companies for collaborative research work.

• Their main strength is R & D, sale and marketing of Lipiter, Viagra and celebrex.

• Along with the increased production, Pfizer’s marketing policy includes their products on the prescription writings. This task is done by directly targeting the customers, approaching physicians and targeting drugs management organizations directly.

Weaknesses

• In latter stages of production they often discontinue the activity, increasing its demand.

• Not specifically working in the area of primary concern in the drug markets including CV and CNS.

• Its co marketing with other companies and merging with other pharmaceuticals can halter its global popularity.

Opportunities

• Bought King pharmaceutical for $3.6 billion which would open up more manufacture and sales adding to the capital of the company (Carrie, 2009).

• Pfizer is reconstructing its strategically approach by cutting the manufacture cost.

• High profits, revenues and funds are available to uplift the company’s progress.

• Expansion of the biologic pharmacy market.

• Marketing agreements with the leading companies.